Im­muno­Gen's new CEO re­trench­es, ax­ing 65 staffers and look­ing to thin pipeline

Im­muno­Gen’s new CEO is done as­sess­ing the com­pa­ny, and one of his first acts will in­volve swing­ing an ax.

The biotech $IMGN is elim­i­nat­ing 65 jobs, or 17% of the work­force Mark Enyedy in­her­it­ed when he won the job a few months ago. And he wants to li­cense out some “non-core” B-cell lym­phoma pro­gram, the com­pa­ny’s sec­ond-ranked ex­per­i­men­tal drug IMGN529 and coltux­imab rav­tan­sine, as he vows to pur­sue a “lean­er and more ag­ile” com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER